Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:30 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 832 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Graft vs Host Disease Clear all
Completed Phase 2 Interventional Results available

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

NCT00660530
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Disease
Interventions
Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 1Phase 2 Interventional

Keratinocyte Growth Factor to Prevent Acute GVHD

NCT00031148
View directory record Official record
Conditions
Graft-vs-Host Disease
Interventions
Recombinant Human Keratinocyte Growth Factor (rHuKGF)
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
3 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 1, 2026, 1:30 PM EST
Completed No phase listed Observational

Imaging and Understanding BOS in Lung Transplantation

NCT02316392
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Hyperpolarized Helium-3 MRI
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Nov 1, 2026, 1:30 PM EST
Terminated Not applicable Interventional Results available

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

NCT00255684
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Rochester
Other
Eligibility
Up to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Nov 1, 2026, 1:30 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents

NCT00948519
View directory record Official record
Conditions
Rhinosinusitis
Interventions
Laser + ICG, Laser only
Device
Lead sponsor
New York Head & Neck Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Nov 1, 2026, 1:30 PM EST
Terminated Not applicable Interventional

Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT03102060
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient
Interventions
Dietary Intervention, Laboratory Biomarker Analysis
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 2 Interventional

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

NCT00346359
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Nov 1, 2026, 1:30 PM EST
Active, not recruiting No phase listed Observational

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

NCT02611180
View directory record Official record
Conditions
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
Interventions
Skin punch biopsy, Peripheral blood draw
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 1, 2026, 1:30 PM EST
Recruiting Not applicable Interventional

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment

NCT06299683
View directory record Official record
Conditions
Chronic Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Cystitis, Interstitial, Cystitis, Chronic Interstitial, Interstitial Cystitis, Interstitial Cystitis, Chronic, Interstitial Cystitis (Chronic) With Hematuria, Interstitial Cystitis (Chronic) Without Hematuria, Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
Psychosocial Treatment, Pelvic Floor Physical Therapy
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 1, 2026, 1:30 PM EST
No Longer Available No phase listed Expanded access

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

NCT00826046
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Prochymal®
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
U.S. locations
3
States / cities
Beech Grove, Indiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Nov 1, 2026, 1:30 PM EST
Terminated Phase 2 Interventional

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Nov 1, 2026, 1:30 PM EST
Completed Not applicable Interventional Results available

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

NCT00350545
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Rituximab, Prednisone, Cyclosporine A, tacrolimus
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Nov 1, 2026, 1:30 PM EST
Terminated Phase 2 Interventional Results available

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

NCT02169505
View directory record Official record
Conditions
Lymphoma
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Nov 1, 2026, 1:30 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

NCT03597594
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine, Thiotepa, CliniMACS, Donor Lymphocyte Infusion
Drug · Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 1:30 PM EST
Withdrawn Phase 1 Interventional

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

NCT02526329
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
donor regulatory T lymphocytes, laboratory biomarker analysis
Biological · Other
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Nov 1, 2026, 1:30 PM EST
Terminated Phase 2 Interventional Results available

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

NCT00450983
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Genetic + 3 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 1 Interventional

FMT In High-Risk Acute GVHD After ALLO HCT

NCT04139577
View directory record Official record
Conditions
Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
Interventions
Fecal Microbiota Transplant
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 3 Interventional Results available

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

NCT01295710
View directory record Official record
Conditions
GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
Interventions
US-ATG-F, Placebo
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 2 Interventional Results available

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

NCT04112810
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Tildrakizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Nov 1, 2026, 1:30 PM EST
Completed No phase listed Observational

Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research

NCT01851382
View directory record Official record
Conditions
Graft vs Host Disease, Healthy Volunteer, Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 1 Interventional

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT05121142
View directory record Official record
Conditions
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Nov 1, 2026, 1:30 PM EST
Completed Phase 1 Interventional

Brentuximab Vedotin for Steroid Refractory GvHD

NCT01596218
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Nov 1, 2026, 1:30 PM EST